SNS-032, alvocidib, and a VEGF inhibitor control agent (axitinib) were also separately evaluated in two sarcomatoid RCC cell lines (UOK127 and RCJ41-T2; not included in the CTRP or PRISM screens) and three non-sarcomatoid RCC cell lines (Caki-2, KMRC-20, and KMRC-2; included in the CTRP or PRISM screens). The gene discussed is VEGFA; the disease is renal cell carcinoma.